National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

For the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results. A positive test of the clinical response to Duodopa® administered via a temporary nasoduodenal tube is required before a permanent tube is inserted.

Rapid Review

Commenced Completed Outcome
13/03/2013 16/04/2013 Full Pharmacoeconomic Evaluation Recommended.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
26/09/2013 30/12/2013 Reimbursement not recommended at the submitted price

Summary

December 2015

The HSE has approved reimbursement following confidential price negotiations.

 The HSE has now requested a full HTA for this product 25th June 2018
Full pharmacoeconomic assessment commissioned by HSE 25/06/2018
Pre-submission consultation with Applicant 05/07/2018
Submission received from Applicant 10/09/2018
Preliminary review sent to Applicant 05/12/2018
NCPE assessment re-commenced 14/01/2019
Preliminary review II sent to Applicant 30/01/2019
NCPE assessment re-commenced 15/02/2019
Factual accuracy sent to Applicant 19/03/2019
NCPE assessment re-commenced 02/04/2019
Current status NCPE assessment ongoing